Vertikal RMS Launches Hawk-I: AI-Powered Revolution in Certificate of Insurance Compliance Tracking
With Hawk-I, Vertikal RMS takes a significant leap toward fully automated insurance compliance tracking, empowering organizations to operate faster, smarter, and with greater confidence.
Share
"Hawk-I represents a transformative leap forward in third-party risk management. By automating the COI review process, we're empowering organizations to proactively manage risk, ensure compliance, and protect their operations from potential liabilities.'
- Robert Rodriguez, Chief Operating Officer, Vertikal RMS
For decades, organizations have grappled with the challenges of manually reviewing and tracking COIs from vendors, contractors, and suppliers—a process often fraught with delays, human error, and inconsistencies. Hawk-I addresses these issues head-on by leveraging advanced AI technologies, including natural language processing (NLP) and machine learning, to extract and analyze insurance data from both structured and unstructured sections of ACORD Certificates of Insurance. This enables real-time compliance assessments, significantly reducing turnaround times from days to mere seconds.
Key Features and Benefits of Hawk-I:
Instant COI Data Extraction: Accurately captures policy information from Certificates of Insurance, minimizing errors and manual data entry.
Real-Time Compliance Status: Provides immediate feedback on compliance, enabling swift action to address any issues.
Cost Efficiency: Reduces administrative burdens and associated costs by automating labor-intensive processes.
Enhanced Collaboration: Facilitates better communication between compliance officers, procurement teams, and vendors through transparent and responsive processes.
Hawk-I's adaptability extends beyond COI management, with capabilities to interpret other business documents and compliance records, making it a versatile asset across various departments and industries.
This launch underscores Vertikal's commitment to innovation and excellence in risk management solutions. By integrating Hawk-I into CertFocus, Vertikal continues to provide clients with cutting-edge tools to navigate the complexities of third-party risk and compliance.
About Vertikal RMS
Vertikal RMS is a premier provider of risk management technology solutions, specializing in Certificate of Insurance tracking and vendor prequalification. With a focus on innovation and customer success, Vertikal delivers scalable, integrated, and customizable platforms designed to mitigate risk and enhance operational efficiency.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
12 hours ago
- Business Wire
Central Pacific Financial Corp. Announces Conference Call to Discuss Second Quarter 2025 Financial Results
HONOLULU--(BUSINESS WIRE)--Central Pacific Financial Corp. (NYSE: CPF), parent company of Central Pacific Bank, will release its second quarter 2025 earnings on July 25, 2025, before the open of the New York Stock Exchange. Management will review the results by conference call and live audio webcast beginning at 2:00 p.m. Eastern Time (8:00 a.m. Hawaii Time) on July 25, 2025. Interested parties may listen to the conference by calling 1-800-715-9871 (conference ID: 6299769), or by listening to the webcast on the company's investor relations website at A replay of the call will be available through August 24, 2025 by dialing 1-800-770-2030 (conference ID: 6299769) and on the company's website. About Central Pacific Financial Corp. Central Pacific Financial Corp. is a Hawaii-based bank holding company with approximately $7.41 billion in assets as of March 31, 2025. Central Pacific Bank, its primary subsidiary, operates 27 branches and 55 ATMs in the State of Hawaii. For additional information, please visit the Company's website at: Equal Housing Lender Member FDIC NYSE Listed CPF
Business Wire
12 hours ago
- Business Wire
Kirby McInerney LLP Urges Investors in DoubleVerify Holdings, Inc. (DV) to Inquire About Their Rights in Class Action Lawsuit
NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP reminds investors of the July 21, 2025, deadline to seek the role of lead plaintiff in a federal securities class action filed on behalf of investors who acquired DoubleVerify Holdings, Inc. ('DoubleVerify' or the 'Company') (NYSE:DV) securities during the period from November 10, 2023, through February 27, 2025 ('the Class Period'). [ LEARN MORE ABOUT THE CLASS ACTION ] On February 28, 2024, DoubleVerify issued lower revenue growth expectations for the first quarter of 2024 due to 'a slow start by brand advertisers and a slow ramp by recently signed new large customers.' On this news, the price of DoubleVerify shares declined by $8.25 per share, or approximately 21%, from $39.24 per share on February 28, 2024, to close at $30.89 on February 29, 2024. On May 7, 2024, in connection with its first quarter 2024 earnings report, DoubleVerify surprised analysts by cutting its full-year 2024 revenue outlook due to customers that were pulling back on their ad spending. On this news, the price of DoubleVerify shares declined by $11.79 per share, or approximately 38%, from $30.57 per share on May 7, 2024, to close at $18.78 on May 8, 2024. Then, on February 27, 2025, when DoubleVerify reported lower-than-expected fourth quarter 2024 sales and earnings due in part to reduced customer spending, DoubleVerify also disclosed that the shift of ad dollars from open exchanges to closed platforms was negatively impacting the Company. On this news, the price of DoubleVerify shares declined by $7.83, or approximately 36%, from $21.73 per share on February 27, 2025, to close at $13.90 on February 28, 2025. Finally, on March 28, 2025, market research company Adalytics Research, LLC released a report claiming that DoubleVerify's web advertisement verification and fraud protection services are ineffective, and that DoubleVerify customers are regularly billed for ad impressions served to declared bots operating out of known data center server farms. On the same day, The Wall Street Journal reported that DoubleVerify regularly misses detection of nonhuman traffic in contradiction to the Company's claims that it helps brand avoid serving ads to nonhuman bot accounts. If you purchased or otherwise acquired DoubleVerify securities, have information, or would like to learn more about this investigation, please contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@ or fill out the form below, to discuss your rights or interests with respect to these matters without any cost to you. [ CONTACT FORM ] Kirby McInerney LLP is a New York-based plaintiffs' law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm's efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP's website. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Business Wire
13 hours ago
- Business Wire
Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation ('Quanterix' or the 'Company') (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced that on July 8, 2025, the Company approved inducement grants of restricted stock units ('RSUs') representing 267,269 shares of Quanterix common stock to twenty employees newly-hired in connection with the acquisition of Akoya Biosciences, Inc. The equity awards were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or her acceptance of employment with the Company. The RSUs vest in full on the one year anniversary of the grant date, subject to the applicable individual's continued employment with the Company or one of its subsidiaries through the vesting date. About Quanterix Quanterix is a global leader in ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development. Its proprietary Simoa ® technology delivers industry-leading sensitivity, allowing researchers to detect and quantify biomarkers in blood and other fluids at concentrations far below traditional limits. With more than 3,400 peer-reviewed publications, Quanterix has been a trusted partner to the scientific community for nearly two decades. In 2025, Quanterix acquired Akoya Biosciences, The Spatial Biology Company ®, adding multiplexed tissue imaging with single-cell resolution to its portfolio. Together, the combined company offers a uniquely integrated platform that connects biology across blood and tissue—advancing precision medicine from discovery to diagnostics. Learn more at
